Overall survival and response to radiation and targeted therapies among patients with renal cell carcinoma brain metastases

Restricted access

OBJECTIVE

The object of this retrospective study was to investigate the impact of targeted therapies on overall survival (OS), distant intracranial failure, local failure, and radiation necrosis among patients treated with radiation therapy for renal cell carcinoma (RCC) metastases to the brain.

METHODS

All patients diagnosed with RCC brain metastasis (BM) between 1998 and 2015 at a single institution were included in this study. The primary outcome was OS, and secondary outcomes included local failure, distant intracranial failure, and radiation necrosis. The timing of targeted therapies was recorded. Multivariate Cox proportional-hazards regression was used to model OS, while multivariate competing-risks regression was used to model local failure, distant intracranial failure, and radiation necrosis, with death as a competing risk.

RESULTS

Three hundred seventy-six patients presented with 912 RCC BMs. Median OS was 9.7 months. Consistent with the previously validated diagnosis-specific graded prognostic assessment (DS-GPA) for RCC BM, Karnofsky Performance Status (KPS) and number of BMs were the only factors prognostic for OS. One hundred forty-seven patients (39%) received vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs). Median OS was significantly greater among patients receiving TKIs (16.8 vs 7.3 months, p < 0.001). Following multivariate analysis, KPS, number of metastases, and TKI use remained significantly associated with OS.

The crude incidence of local failure was 14.9%, with a 12-month cumulative incidence of 13.4%. TKIs did not significantly decrease the 12-month cumulative incidence of local failure (11.4% vs 14.5%, p = 0.11). Following multivariate analysis, age, number of BMs, and lesion size remained associated with local failure. The 12-month cumulative incidence of radiation necrosis was 8.0%. Use of TKIs within 30 days of SRS was associated with a significantly increased 12-month cumulative incidence of radiation necrosis (10.9% vs 6.4%, p = 0.04).

CONCLUSIONS

Use of targeted therapies in patients with RCC BM treated with intracranial SRS was associated with improved OS. However, the use of TKIs within 30 days of SRS increases the rate of radiation necrosis without improving local control or reducing distant intracranial failure. Prospective studies are warranted to determine the optimal timing to reduce the rate of necrosis without detracting from survival.

ABBREVIATIONS BM = brain metastasis; DS-GPA = diagnosis-specific graded prognostic assessment; KPS = Karnofsky Performance Status; mTOR = mammalian target of rapamycin; OS = overall survival; RCC = renal cell carcinoma; SRS = stereotactic radiosurgery; TKI = tyrosine kinase inhibitor; VEGFR = vascular endothelial growth factor receptor; WBRT = whole-brain radiation therapy.

Article Information

Correspondence Samuel T. Chao: Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. chaos@ccf.org.

INCLUDE WHEN CITING Published online January 18, 2019; DOI: 10.3171/2018.8.JNS182100.

Disclosures Dr. Ahluwalia has direct stock ownership in Mimivax; has been a consultant for Monteris Medical, BMS, Astrazeneca, VBI Vacines, Abbvie, Varian, and Flatiron; and has received support from Novartis, Abbvie, Incyte, Astrazeneca, Novocure, Bayer, Merck, and Pharmacyclics for non–study-related clinical or research effort. Dr. Rini has received support from Pfizer for non–study-related clinical or research effort. Dr. Chao has received honorarium from Varian Medical System.

© AANS, except where prohibited by US copyright law.

Headings

Figures

  • View in gallery

    Overall survival among patients with RCC BMs treated with and without VEGFR TKIs (A), treated with and without mTOR inhibitors (B), and stratified by the DS-GPA group (C).

  • View in gallery

    Cumulative incidence of local failure among patients undergoing SRS and treated with and without VEGFR TKIs (A), stratified by maximum lesion diameter (B). Cumulative incidence of radiation necrosis among patients undergoing SRS and treated with and without VEGFR TKIs (C), stratified by maximum lesion diameter (D).

References

  • 1

    Anker CJGrossmann KFAtkins MBSuneja GTarhini AAKirkwood JM: Avoiding severe toxicity from combined BRAF inhibitor and radiation treatment: consensus guidelines from the Eastern Cooperative Oncology Group (ECOG). Int J Radiat Oncol Biol Phys 95:6326462016

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2

    Barnholtz-Sloan JSSloan AEDavis FGVigneau FDLai PSawaya RE: Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22:286528722004

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3

    Bates JEYoun PPeterson CR IIIUsuki KYWalter KAOkunieff P: Radiotherapy for brain metastases from renal cell carcinoma in the targeted therapy era: the University of Rochester experience. Am J Clin Oncol 40:4394432017

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4

    Bowman IALe TChristie ABrugarolas J: Incidence of brain metastases in metastatic renal cell carcinoma in the era of targeted therapies. J Clin Oncol 34 (15 Suppl):e161032016 (Abstract)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5

    Brooks CSheu TBridges KMason KKuban DMathew P: Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer. Radiat Oncol 7:1542012

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6

    Brugarolas J: Renal-cell carcinoma—molecular pathways and therapies. N Engl J Med 356:1851872007

  • 7

    Cao WGMa TLi JFLi HJi YBChen XH: [Effect of gefitinib on radiosensitivity of gastric cancer cell lines.] Chin J Cancer 26:133013352007 (Chinese)

    • Search Google Scholar
    • Export Citation
  • 8

    Chang ELSelek UHassenbusch SJ IIIMaor MHAllen PKMahajan A: Outcome variation among “radioresistant” brain metastases treated with stereotactic radiosurgery. Neurosurgery 56:9369452005

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9

    Chao STAhluwalia MSBarnett GHStevens GHMurphy ESStockham AL: Challenges with the diagnosis and treatment of cerebral radiation necrosis. Int J Radiat Oncol Biol Phys 87:4494572013

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10

    Cochran DCChan MDAklilu MLovato JFAlphonse NKBourland JD: The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery. J Neurosurg 116:9789832012

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11

    Cuneo KCGeng LFu AOrton DHallahan DEChakravarthy AB: SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. Int J Radiat Oncol Biol Phys 71:8738792008

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12

    Dudek AZRaza AChi MSinghal MOberoi RMittapalli RK: Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors. Clin Genitourin Cancer 11:1551602013

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13

    Fine JPGray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:4965091999

  • 14

    Goyal LKSuh JHReddy CABarnett GH: The role of whole brain radiotherapy and stereotactic radiosurgery on brain metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys 47:100710122000

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15

    Gray R: A Class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:114111541988

  • 16

    Halperin ECHarisiadis L: The role of radiation therapy in the management of metastatic renal cell carcinoma. Cancer 51:6146171983

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17

    Hillman GGSingh-Gupta VAl-Bashir AKYunker CKJoiner MCSarkar FH: Monitoring sunitinib-induced vascular effects to optimize radiotherapy combined with soy isoflavones in murine xenograft tumor. Transl Oncol 4:1101212011

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18

    Hudes GCarducci MTomczak PDutcher JFiglin RKapoor A: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:227122812007

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19

    Hutson TEThoreson GRFiglin RARini BI: The evolution of systemic therapy in metastatic renal cell carcinoma. Am Soc Clin Oncol Educ Book 35:1131172016

  • 20

    Johnson AGRuiz JHughes RPage BRIsom SLucas JT: Impact of systemic targeted agents on the clinical outcomes of patients with brain metastases. Oncotarget 6:18945189552015

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21

    Magnuson WJYeung JTGuillod PDGettinger SNYu JBChiang VL: Impact of deferring radiation therapy in patients with epidermal growth factor receptor-mutant non-small cell lung cancer who develop brain metastases. Int J Radiat Oncol Biol Phys 95:6736792016

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22

    Massard CZonierek JGross-Goupil MFizazi KSzczylik CEscudier B: Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol 21:102710312010

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23

    Miller JABalagamwala EHAngelov LSuh JHRini BGarcia JA: Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma. J Neurosurg Spine 25:7667742016

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24

    Miller JABennett EEXiao RKotecha RChao STVogelbaum MA: Association between radiation necrosis and tumor biology after stereotactic radiosurgery for brain metastasis. Int J Radiat Oncol Biol Phys 96:106010692016

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25

    Motzer RJEscudier BOudard SHutson TEPorta CBracarda S: Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116:425642652010

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26

    Motzer RJHutson TETomczak PMichaelson MDBukowski RMOudard S: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:358435902009

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27

    Motzer RJHutson TETomczak PMichaelson MDBukowski RMRixe O: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:1151242007

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28

    Motzer RJRini BIBukowski RMCurti BDGeorge DJHudes GR: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:251625242006

  • 29

    National Comprehensive Cancer Network: Kidney Cancer Version 3.2016. Fort Washington, PA: NCCN2016

  • 30

    Patchell RATibbs PARegine WFDempsey RJMohiuddin MKryscio RJ: Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280:148514891998

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 31

    Saleem WSuzuki YMobaraki AYoshida YNoda SSaitoh JI: Reduction of nitric oxide level enhances the radiosensitivity of hypoxic non-small cell lung cancer. Cancer Sci 102:215021562011

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32

    Schouten LJRutten JHuveneers HATwijnstra A: Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94:269827052002

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 33

    Shaw EScott CSouhami LDinapoli RKline RLoeffler J: Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 47:2912982000

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34

    Sheehan JPSun MHKondziolka DFlickinger JLunsford LD: Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control. J Neurosurg 98:3423492003

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35

    Siegel RLMiller KDJemal A: Cancer statistics, 2016. CA Cancer J Clin 66:7302016

  • 36

    Sneed PKMendez JVemer-van den Hoek JGSeymour ZAMa LMolinaro AM: Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors. J Neurosurg 123:3733862015

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37

    Solberg TDNearman JMullins JLi SBaranowska-Kortylewicz J: Correlation between tumor growth delay and expression of cancer and host VEGF, VEGFR2, and osteopontin in response to radiotherapy. Int J Radiat Oncol Biol Phys 72:9189262008

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38

    Sperduto PWChao STSneed PKLuo XSuh JRoberge D: Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 77:6556612010

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39

    Sperduto PWDeegan BJLi JJethwa KRBrown PDLockney N: Effect of targeted therapies on prognostic factors, patterns of care, and survival in patients with renal cell carcinoma and brain metastases. Int J Radiat Oncol Biol Phys 101:8458532018

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40

    Staehler MHaseke NNuhn PTüllmann CKarl ASiebels M: Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma. BJU Int 108:6736782011

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41

    Sternberg CNHawkins REWagstaff JSalman PMardiak JBarrios CH: A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 49:128712962013

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42

    Tsai YCHo PYTzen KYTuan TFLiu WLCheng AL: Synergistic blockade of EGFR and HER2 by new-generation EGFR tyrosine kinase inhibitor enhances radiation effect in bladder cancer cells. Mol Cancer Ther 14:8108202015

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43

    Verma JJonasch EAllen PKWeinberg JSTannir NChang EL: The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma. Am J Clin Oncol 36:6206242013

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44

    Vogl UMBojic MLamm WFrischer JMPichelmayer OKramer G: Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma. BMC Cancer 10:4802010

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45

    Wong ETHuberman MLu XQMahadevan A: Bevacizumab reverses cerebral radiation necrosis. J Clin Oncol 26:564956502008

  • 46

    Wowra BSiebels MMuacevic AKreth FWMack AHofstetter A: Repeated gamma knife surgery for multiple brain metastases from renal cell carcinoma. J Neurosurg 97:7857932002

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47

    Wrónski MMaor MHDavis BJSawaya RLevin VA: External radiation of brain metastases from renal carcinoma: a retrospective study of 119 patients from the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys 37:7537591997

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 48

    Zhang HPTakayama KSu BJiao XDLi RWang JJ: Effect of sunitinib combined with ionizing radiation on endothelial cells. J Radiat Res (Tokyo) 52:182011

    • Crossref
    • Search Google Scholar
    • Export Citation

TrendMD

Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 687 687 52
Full Text Views 127 127 9
PDF Downloads 103 103 8
EPUB Downloads 0 0 0

PubMed

Google Scholar